Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences
Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinet...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2020-06-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/12357 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140931477471232 |
|---|---|
| author | Hanne Haahr Tim Heise |
| author_facet | Hanne Haahr Tim Heise |
| author_sort | Hanne Haahr |
| collection | DOAJ |
| description | Fast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products. |
| format | Article |
| id | doaj-art-8f6ea16d2b274e568069cac42f9f1865 |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-8f6ea16d2b274e568069cac42f9f18652025-08-20T02:29:39ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782020-06-0123214016010.14341/DM1235710640Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequencesHanne Haahr0Tim Heise1Novo Nordisk A/SProfilFast-acting insulin aspart (faster aspart) is insulin aspart (IAsp) with two added excipients, L-arginine and niacinamide, to ensure formulation stability with accelerated initial absorption after subcutaneous administration compared with previously developed rapid-acting insulins. The pharmacokinetic/pharmacodynamic properties of faster aspart have been characterised in clinical pharmacology trials with comparable overall methodology. In subjects with type 1 (T1D) or type 2 (T2D) diabetes, the serum IAsp concentration-time and glucose-lowering effect profiles are left-shifted for faster aspart compared with IAsp. In addition, faster aspart provides earlier onset, doubling of initial exposure, and an up to 2.5-fold increase in initial glucose-lowering effect within 30 min of subcutaneous injection, as well as earlier offset of exposure and effect. Similar results have been shown using continuous subcutaneous insulin infusion (CSII). The improved pharmacological properties of faster aspart versus IAsp are consistent across populations, i.e. in the elderly, children, adolescents and the Japanese. Thus, the faster aspart pharmacological characteristics more closely resemble the mealtime insulin secretion in healthy individuals, giving faster aspart the potential to further improve postprandial glucose control in subjects with diabetes. Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.https://www.dia-endojournals.ru/jour/article/view/12357faster aspartpharmacokineticpharmacodynamicclamp |
| spellingShingle | Hanne Haahr Tim Heise Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences Сахарный диабет faster aspart pharmacokinetic pharmacodynamic clamp |
| title | Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| title_full | Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| title_fullStr | Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| title_full_unstemmed | Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| title_short | Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| title_sort | fast acting insulin aspart a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences |
| topic | faster aspart pharmacokinetic pharmacodynamic clamp |
| url | https://www.dia-endojournals.ru/jour/article/view/12357 |
| work_keys_str_mv | AT hannehaahr fastactinginsulinaspartareviewofitspharmacokineticandpharmacodynamicpropertiesandtheclinicalconsequences AT timheise fastactinginsulinaspartareviewofitspharmacokineticandpharmacodynamicpropertiesandtheclinicalconsequences |